Maravai Lifesciences Holdings (MRVI) EBT (2020 - 2026)

Maravai Lifesciences Holdings' EBT history runs 7 years deep, the most recent figure standing at -$6.5 million for Q1 2026.

• On a quarterly basis, EBT rose 87.61% year-over-year to -$6.5 million in Q1 2026; TTM through Mar 2026 was -$188.8 million, a 35.29% increase from a year earlier, with the FY2025 full-year figure at -$235.0 million, up 10.14% from the prior year.
• EBT rose to -$6.5 million in Q1 2026 per MRVI's latest filing, from -$63.0 million in the prior quarter.
• Across five years, EBT topped out at $656.2 million in Q4 2023 and bottomed at -$172.1 million in Q3 2024.
• The 5-year median for EBT is -$20.6 million (2023), against an average of $39.2 million.
• Across the five-year window, EBT jumped 584.41% in 2023 and plunged 737.15% in 2024, its largest moves.
• Year by year, EBT stood at $95.9 million in 2022, then soared by 584.41% to $656.2 million in 2023, then sank by 107.02% to -$46.1 million in 2024, then sank by 36.76% to -$63.0 million in 2025, then soared by 89.64% to -$6.5 million in 2026.
• Per Business Quant, the three latest MRVI EBT figures stand at -$6.5 million (Q1 2026), -$63.0 million (Q4 2025), and -$45.1 million (Q3 2025).